Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Node-Sparing Short-Course Radiotherapy Followed by First-Line Chemotherapy Plus Bevacizumab and PD-1 Inhibitor Versus Chemotherapy Plus Bevacizumab Alone in Metastatic pMMR/MSS Colorectal Cancer: A Randomized, Phase II/III Trial (MODIFI-CRC)

NCT06958419 is registered in ClinicalTrials.gov with Sixth Affiliated Hospital, Sun Yat-sen University as lead sponsor.

NCT NCT06958419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06958419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Node-Sparing Short-Course Radiotherapy Followed by First-Line Chemotherapy Plus Bevacizumab and PD-1 Inhibitor Versus Chemotherapy Plus Bevacizumab Alone in Metastatic pMMR/MSS Colorectal Cancer: A Randomized, Phase II/III Trial (MODIFI-CRC)
Lead sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 1, 2025
Completion date
December 31, 2031
Enrollment
286 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune checkpoint therapy, metastatic colorectal cancer (crc), radiotherapy